Journal of electrocardiology
-
For the past several years ECRI Institute has published a list of Top Ten Health Technology Hazards. This list is based on ECRI's extensive research in health technology safety and on data provided to its problemreporting systems. For every year that the Top Ten list has been published, Alarm Hazards have been at or near the top of the list. ⋯ It also requires careful selection of alarm setting criteria for each clinical care area. This article will overview the clinical alarm problems that have been identified through ECRI Institute's research and analysis of various problem reporting databases, including those operated by ECRI Institute. It will also highlight suggestions for improvement, particularly from a technology design and technology management perspective.
-
It is well accepted that early reperfusion is beneficial in patients with acute myocardial infarction presenting with ST elevation (STE). Earlier studies suggested lack of beneficial effects in patients presenting without STE and even with ST depression. Currently, time to reperfusion is considered to be a quality of care measure, and the latest American College of Cardiology/American Heart Association guidelines for the treatment of STE acute myocardial infarction (STEMI) emphasize that the physician at the emergency department should make reperfusion decisions within 10 minutes of performing the initial electrocardiogram (ECG). ⋯ It should be remembered that patients presenting with chest pain and showing benign pattern of NISTE (eg, "early repolarization" or STE secondary to left ventricular hypertrophy) may have true ischemic pain and non-STE myocardial infarction or even STEMI on top of the baseline benign pattern. It seems that, in the "real world," the ability of physicians to differentiate NISTE from STEMI based on the presenting ECG pattern widely varies and depends on the prevalence of baseline NISTE in the patient population. Further studies are needed to assess the ability of various ECG criteria to accurately differentiate between STEMI and NISTE.
-
Review Meta Analysis
Time to reperfusion in acute myocardial infarction. It is time to reduce it!
Mortality from ST-segment elevation myocardial infarction remains high, with most deaths occurring before hospital admission. Despite effective pre- and in-hospital reperfusion strategies becoming standard over the past 2 decades, time-to-admission and time-to-treatment remain prolonged. We reviewed temporal trends in these times in published clinical trials. ⋯ Time-to-admission and time-to-treatment for ST-segment elevation myocardial infarction are still prolonged. Resources should be directed to early recognition of the acute myocardial infarction, improved utilization of emergency services for transportation, and prehospital diagnosis and triaging. Ambulances equipped with wireless capability to transmit electrocardiograms to the on-call cardiologist seem to be promising tools to achieve earlier diagnosis and triaging with high diagnostic sensitivity and specificity.
-
Although there are rising public expectations about the prospects for new therapies based on advances in biomedical discoveries, the rate of new product submissions to the Food and Drug Administration (FDA) has not been increasing. Alarmingly, over the past 6 years, there has been a 30% decline in submissions. The reasons for this are multifactorial and include new science not at its full potential, mergers/business arrangements have decreased candidates, chronic disease is harder to study, the failure rate has not improved, and rapidly escalating costs and complexity. ⋯ The partnership is designed to expand product opportunities by sharing existing knowledge and data, allowing the development of enabling standards, to improve drug development and approval. A central tenant of Critical Path is a focus on the evaluative science of the drug approval process, including both efficacy and safety measures. The FDA Electrocardiogram Warehouse is 1 example where a government resource could be used by a confluence of groups to improve the science surrounding important components of the drug approval process such as cardiac safety evaluation.